SpyGlass Pharma, Inc.
SGP
$26.20
$1.034.09%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 06/30/2025 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 11.03M | 6.87M | 5.92M | 1.96M | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 21.97M | 15.41M | 13.63M | 9.30M | |
| Operating Income | -21.97M | -15.41M | -13.63M | -9.30M | |
| Income Before Tax | -19.86M | -13.82M | -12.56M | -8.68M | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -19.86M | -13.82M | -12.56M | -8.68M | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -19.86M | -13.82M | -12.56M | -8.68M | |
| EBIT | -21.97M | -15.41M | -13.63M | -9.30M | |
| EBITDA | -21.63M | -15.09M | -13.41M | -9.16M | |
| EPS Basic | -0.59 | -0.69 | -5.72 | -3.81 | |
| Normalized Basic EPS | -0.37 | -0.43 | -3.57 | -2.38 | |
| EPS Diluted | -0.59 | -0.69 | -5.73 | -3.81 | |
| Normalized Diluted EPS | -0.37 | -0.43 | -3.57 | -2.38 | |
| Average Basic Shares Outstanding | 33.44M | 19.93M | 2.20M | 2.28M | |
| Average Diluted Shares Outstanding | 33.44M | 19.93M | 2.20M | 2.28M | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |